Junshi CEO Ning Li (Junshi)
September 29, 2020 07:13 AM EDT
R&D

Rac­ing ahead of Mer­ck and In­novent, Jun­shi de­clares PhI­II suc­cess on can­cer that won them 'break­through' sta­tus

Jason Mast

Editor

Ear­ly this month, the FDA hand­ed Jun­shi Bio­sciences an agency first: A break­through des­ig­na­tion for a PD-(L)1 ther­a­py out of Chi­na. Now, the Shang­hai …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times